2-Substituted benzisothiazolones

Claim 1

A compound of the formula (V) ##STR26## or a pharmaceutically acceptable non-toxic acid addition salt thereof where there is a basic nitrogen in the molecule wherein R 1 and R 2 are the same or different and each is hydrogen, lower alkyl, lower alkoxy, halo-lower alkyl, nitro, amino, acetylamino or halogen, or R 1 and R 2 when attached to adjacent carbon atoms from an alkylene moiety of 3 to 6 carbon atoms or an oxyalkyleneoxy moiety of 1 to 3 carbon atoms; R 3 is a nitrogen-containing heterocyclic ring unsubstituted or substituted by lower alkyl, carboxy or alkoxycarbonyl; and X is a bond or straight or branched chain alkylene of 1 to 12 carbon atoms.

Claim 13

A method of inhibiting platelet aggregation in humans and animals, of inhibiting thromboses in humans and animals and for treating arterial thromboses in humans and animals which comprises administering to a human or animal in need thereof, in an amount sufficient to inhibit platelet aggregation, an amount sufficient to inhibit the formation of thrombs or an amount sufficient to dissolve thromboses, a compound of the formula ##STR28## or a pharmaceutically acceptable nontoxic acid addition salt thereof when there is a basic nitrogen atom in the molecule, wherein R 1 and R 2 are the same or different and each is hydrogen, lower alkyl, lower alkoxy, halo-lower alkyl, nitro, amino, acetylamino or halogen; or R 1 together with R 2 when attached to adjacent carbon atoms form an alkylene moiety of 3 to 6 carbon atoms or an oxyalkyleneoxy moiety of 1 to 3 carbon atoms; X is a bond or a straight or branched chain alkylene of 1 to 12 carbon atoms; and R 3 is a nitrogen-containing heterocyclic ring unsubstituted or substituted by lower alkyl, carboxy or alkoxycarbonyl.

Claim 14

A method of inhibiting platelet aggregation in humans and animals, of inhibiting thromboses in humans and animals and for treating arterial thromboses in humans and animals which comprises administering to a human or animal in need thereof, in an amount sufficient to inhibit platelet aggregation, an amount sufficient to inhibit the formation of thrombs or an amount sufficient to dissolve thromboses, a compound of the formula ##STR28## or a pharmaceutically acceptable nontoxic acid addition salt thereof when there is a basic nitrogen atom in the molecule, wherein R 1 and R 2 are the same or different and each is hydrogen, lower alkyl, lower alkoxy, halo-lower alkyl, nitro, amino, acetylamino or halogen; or R 1 together with R 2 when attached to adjacent carbon atoms form an alkylene moiety of 3 to 6 carbon atoms or an oxyalkyleneoxy moiety of 1 to 3 carbon atoms; X is a bond or a straight or branched chain alkylene of 1 to 12 carbon atoms; and R 3 is a nitrogen-containing heterocyclic ring unsubstituted or substituted by lower alkyl, carboxy or alkoxycarbonyl.

Claim 19

A method for inhibiting platelet aggreation in vitro which comprises adding to whole blood or platelet-rich concentrates a compound of the formula: ##STR29## or a pharmaceutically acceptable nontoxic acid addition salt thereof when there is a basic nitrogen atom in the molecule, wherein R 1 and R 2 are the same or different and each is hydrogen, lower alkyl, lower alkoxy, halo-lower alkyl, nitro, amino, acetylamino or halogen; or R 1 and R 2 when attached to adjacent carbon atoms form an alkylene moiety of 3 to 6 carbon atoms or an oxyalkyleneoxy moiety of 1 to 3 carbon atoms; X is a bond or a straight or branched chain alkylene of 1 to 12 carbon atoms; and R 3 is a nitrogen-containing heterocyclic ring unsubstituted or substituted by lower alkyl, carboxy or alkoxycarbonyl; in combination with a pharmaceutically acceptable carrier.

Claim 20

A method for inhibiting platelet aggreation in vitro which comprises adding to whole blood or platelet-rich concentrates a compound of the formula: ##STR29## or a pharmaceutically acceptable nontoxic acid addition salt thereof when there is a basic nitrogen atom in the molecule, wherein R 1 and R 2 are the same or different and each is hydrogen, lower alkyl, lower alkoxy, halo-lower alkyl, nitro, amino, acetylamino or halogen; or R 1 and R 2 when attached to adjacent carbon atoms form an alkylene moiety of 3 to 6 carbon atoms or an oxyalkyleneoxy moiety of 1 to 3 carbon atoms; X is a bond or a straight or branched chain alkylene of 1 to 12 carbon atoms; and R 3 is a nitrogen-containing heterocyclic ring unsubstituted or substituted by lower alkyl, carboxy or alkoxycarbonyl; in combination with a pharmaceutically acceptable carrier.